Robin M. Hallett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Robin M. Hallett has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Gont
Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
12 shared publications - Bo Kyung Alex Seong
Department of Medical Biophysics, University of Toronto, Toronto, Canada
12 shared publications - Ivette Valencia-Sama
The Hospital for Sick Children
12 shared publications - Lynn Kee
Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
12 shared publications - Meredith S. Irwin
Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
12 shared publications Teresa Adderley
12 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables ST1-ST6 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Supplementary Table 1: Description of TCGA derived mRNA expression cohorts used to examine LIF expression and associated transcript signaturesSupplementary Table 2: Transcription signatures used to identify biological processes and cell types correlated with LIF expression.Supplementary Table 3: GSEA results of REACTOME pathway gene sets for enriched gene sets in LIF treated macrophages. Supplementary Table 4: Leading edge genes selected from GSEA analysis of LIF treated macrophages with REACTOME pathway gene sets Supplementary Table 5: Summary of data collection statistics for crystal structures of MSC-1:LIF co-complex Supplementary Table 6: Summary of interactions between MSC-1 and LIF
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables ST1-ST6 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Supplementary Table 1: Description of TCGA derived mRNA expression cohorts used to examine LIF expression and associated transcript signaturesSupplementary Table 2: Transcription signatures used to identify biological processes and cell types correlated with LIF expression.Supplementary Table 3: GSEA results of REACTOME pathway gene sets for enriched gene sets in LIF treated macrophages. Supplementary Table 4: Leading edge genes selected from GSEA analysis of LIF treated macrophages with REACTOME pathway gene sets Supplementary Table 5: Summary of data collection statistics for crystal structures of MSC-1:LIF co-complex Supplementary Table 6: Summary of interactions between MSC-1 and LIF
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Supplementary Figure 1. Transcriptomic analysis demonstrates an enrichment of immunological pathways in high LIF tumors. Supplementary Figure 2. LIF transcripts are associated with a panel of immunosuppressive macrophage/myeloid signatures across human tumor indications. Supplementary Figure 3. LIF transcripts are specifically associated with suppressive macrophage signatures across human tumor indications. Supplementary Figure 4. LIF transcripts tend to be highly expressed in aggressive tumors. Supplementary Figure 5. LIF drives polarization of immunosuppressive human macrophages. Supplementary Figure 6. RNAseq of LIF induced gene sets in human macrophages predict poor patient outcome and correlate with LIF across human tumor indications. Supplementary Figure 7. Structural analysis of MSC-1 reveals an overlapping epitope with the gp130 binding site and a free cysteine in HCDR3. Supplementary Figure 8. CT26 and MC38 tumors expression LIF protein and monotherapy MSC-1 is well tolerated. Supplementary Figure 9. MSC-1 and anti-PD1 combination is well tolerated and promotes tumor memory in responsive mice.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Supplementary Figure 1. Transcriptomic analysis demonstrates an enrichment of immunological pathways in high LIF tumors. Supplementary Figure 2. LIF transcripts are associated with a panel of immunosuppressive macrophage/myeloid signatures across human tumor indications. Supplementary Figure 3. LIF transcripts are specifically associated with suppressive macrophage signatures across human tumor indications. Supplementary Figure 4. LIF transcripts tend to be highly expressed in aggressive tumors. Supplementary Figure 5. LIF drives polarization of immunosuppressive human macrophages. Supplementary Figure 6. RNAseq of LIF induced gene sets in human macrophages predict poor patient outcome and correlate with LIF across human tumor indications. Supplementary Figure 7. Structural analysis of MSC-1 reveals an overlapping epitope with the gp130 binding site and a free cysteine in HCDR3. Supplementary Figure 8. CT26 and MC38 tumors expression LIF protein and monotherapy MSC-1 is well tolerated. Supplementary Figure 9. MSC-1 and anti-PD1 combination is well tolerated and promotes tumor memory in responsive mice.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Purpose:Leukemia inhibitory factor (LIF) is a multifunctional cytokine with numerous reported roles in cancer and is thought to drive tumor development and progression. Characterization of LIF and clinical-stage LIF inhibitors would increase our understanding of LIF as a therapeutic target.Experimental Design:We first tested the association of LIF expression with transcript signatures representing multiple processes regulating tumor development and progression. Next, we developed MSC-1, a high-affinity therapeutic antibody that potently inhibits LIF signaling and tested it in immune competent animal models of cancer.Results:LIF was associated with signatures of tumor-associated macrophages (TAM) across 7,769 tumor samples spanning 22 solid tumor indications. In human tumors, LIF receptor was highly expressed within the macrophage compartment and LIF treatment drove macrophages to acquire immunosuppressive capacity. MSC-1 potently inhibited LIF signaling by binding an epitope that overlaps with the gp130 receptor binding site on LIF. MSC-1 showed monotherapy efficacy in vivo and drove TAMs to acquire antitumor and proinflammatory function in syngeneic colon cancer mouse models. Combining MSC-1 with anti-PD1 leads to strong antitumor response and a long-term tumor-free survival in a significant proportion of treated mice.Conclusions:Overall, our findings highlight LIF as a therapeutic target for cancer immunotherapy.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Purpose:Leukemia inhibitory factor (LIF) is a multifunctional cytokine with numerous reported roles in cancer and is thought to drive tumor development and progression. Characterization of LIF and clinical-stage LIF inhibitors would increase our understanding of LIF as a therapeutic target.Experimental Design:We first tested the association of LIF expression with transcript signatures representing multiple processes regulating tumor development and progression. Next, we developed MSC-1, a high-affinity therapeutic antibody that potently inhibits LIF signaling and tested it in immune competent animal models of cancer.Results:LIF was associated with signatures of tumor-associated macrophages (TAM) across 7,769 tumor samples spanning 22 solid tumor indications. In human tumors, LIF receptor was highly expressed within the macrophage compartment and LIF treatment drove macrophages to acquire immunosuppressive capacity. MSC-1 potently inhibited LIF signaling by binding an epitope that overlaps with the gp130 receptor binding site on LIF. MSC-1 showed monotherapy efficacy in vivo and drove TAMs to acquire antitumor and proinflammatory function in syngeneic colon cancer mouse models. Combining MSC-1 with anti-PD1 leads to strong antitumor response and a long-term tumor-free survival in a significant proportion of treated mice.Conclusions:Overall, our findings highlight LIF as a therapeutic target for cancer immunotherapy.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
Supplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
Supplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
Supplementary Data from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
Supplementary Data from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
Supplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
Supplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
Supplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
Supplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
Supplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma
Supplementary Figure from Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma